EA028801B1 - Новые ингибиторы sglt1 - Google Patents
Новые ингибиторы sglt1 Download PDFInfo
- Publication number
- EA028801B1 EA028801B1 EA201690749A EA201690749A EA028801B1 EA 028801 B1 EA028801 B1 EA 028801B1 EA 201690749 A EA201690749 A EA 201690749A EA 201690749 A EA201690749 A EA 201690749A EA 028801 B1 EA028801 B1 EA 028801B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diabetes
- mmol
- compound
- added
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901488P | 2013-11-08 | 2013-11-08 | |
| US61/901,488 | 2013-11-08 | ||
| PCT/US2014/063161 WO2015069541A1 (en) | 2013-11-08 | 2014-10-30 | 4-{4-[(1 e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1 -en-1 -yl]-2-methylbenzyl}-5-(propan-2-yl)-1 h-pyrazol-3-yl beta-d- glucopyranoside acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690749A1 EA201690749A1 (ru) | 2016-08-31 |
| EA028801B1 true EA028801B1 (ru) | 2017-12-29 |
Family
ID=51982747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690749A EA028801B1 (ru) | 2013-11-08 | 2014-10-30 | Новые ингибиторы sglt1 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9573970B2 (es) |
| EP (1) | EP3066108B1 (es) |
| JP (1) | JP6197113B2 (es) |
| KR (1) | KR101858881B1 (es) |
| CN (1) | CN105705509B (es) |
| AP (1) | AP2016009180A0 (es) |
| AR (2) | AR098670A1 (es) |
| AU (1) | AU2014347065B2 (es) |
| CA (1) | CA2925128C (es) |
| CL (1) | CL2016000791A1 (es) |
| CR (1) | CR20160165A (es) |
| CY (1) | CY1121096T1 (es) |
| DK (1) | DK3066108T3 (es) |
| DO (1) | DOP2016000067A (es) |
| EA (1) | EA028801B1 (es) |
| ES (1) | ES2703944T3 (es) |
| HR (1) | HRP20182061T1 (es) |
| IL (1) | IL244899B (es) |
| JO (1) | JO3485B1 (es) |
| LT (1) | LT3066108T (es) |
| MA (1) | MA39019A1 (es) |
| MX (1) | MX368174B (es) |
| MY (1) | MY192242A (es) |
| NZ (1) | NZ718118A (es) |
| PE (1) | PE20160884A1 (es) |
| PH (1) | PH12016500851A1 (es) |
| PL (1) | PL3066108T3 (es) |
| PT (1) | PT3066108T (es) |
| RS (1) | RS58050B1 (es) |
| SI (1) | SI3066108T1 (es) |
| SV (1) | SV2016005190A (es) |
| TN (1) | TN2016000112A1 (es) |
| TW (1) | TWI655198B (es) |
| UA (1) | UA118767C2 (es) |
| WO (1) | WO2015069541A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201992726A1 (ru) * | 2017-06-12 | 2020-04-23 | Лингамед, Ллс | Способ получения (s,s)-секоизоларицирезинола диглюкозида и (r,r)-секоизоларицирезинола диглюкозида |
| CN110054657B (zh) | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | 吡喃葡萄糖取代的吡唑化合物及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1544208A1 (en) * | 2002-08-08 | 2005-06-22 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| WO2013169546A1 (en) * | 2012-05-10 | 2013-11-14 | Eli Lilly And Company | Pyrazole compounds as sglt1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU782330B2 (en) | 1999-08-31 | 2005-07-21 | Kissei Pharmaceutical Co. Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| ES2319263T3 (es) | 2001-02-26 | 2009-05-06 | Kissei Pharmaceutical Co., Ltd. | Derivados de glucopiranosilooxipirazol y su utilizacion como medicamentos. |
| EP1400529A4 (en) | 2001-05-30 | 2007-12-19 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF |
| ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| MX2008014512A (es) * | 2006-05-19 | 2008-11-27 | Taisho Pharma Co Ltd | Compuesto de c-fenil glucitol para el tratamiento de diabetes. |
| CN101910189B (zh) | 2007-12-27 | 2013-06-19 | 橘生药品工业株式会社 | 吡唑衍生物的单癸二酸盐 |
| WO2010095768A1 (en) | 2009-02-23 | 2010-08-26 | Taisho Pharmaceutical Co., Ltd. | 4 -isopropylphenyl glucitol compounds as sgltl inhibitors |
| BR112012007349A2 (pt) | 2009-10-02 | 2019-09-24 | Sanofi Sa | uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas. |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2014
- 2014-10-24 AR ARP140104010A patent/AR098670A1/es not_active Application Discontinuation
- 2014-10-26 JO JOP/2014/0310A patent/JO3485B1/ar active
- 2014-10-27 TW TW103137067A patent/TWI655198B/zh active
- 2014-10-30 PT PT14802974T patent/PT3066108T/pt unknown
- 2014-10-30 TN TN2016000112A patent/TN2016000112A1/en unknown
- 2014-10-30 PE PE2016000546A patent/PE20160884A1/es unknown
- 2014-10-30 KR KR1020167011764A patent/KR101858881B1/ko active IP Right Grant
- 2014-10-30 JP JP2016526778A patent/JP6197113B2/ja active Active
- 2014-10-30 DK DK14802974.7T patent/DK3066108T3/da active
- 2014-10-30 RS RS20181382A patent/RS58050B1/sr unknown
- 2014-10-30 CA CA2925128A patent/CA2925128C/en active Active
- 2014-10-30 AU AU2014347065A patent/AU2014347065B2/en active Active
- 2014-10-30 SI SI201430941T patent/SI3066108T1/sl unknown
- 2014-10-30 MA MA39019A patent/MA39019A1/fr unknown
- 2014-10-30 AP AP2016009180A patent/AP2016009180A0/en unknown
- 2014-10-30 MX MX2016005999A patent/MX368174B/es active IP Right Grant
- 2014-10-30 CN CN201480060924.9A patent/CN105705509B/zh active Active
- 2014-10-30 EA EA201690749A patent/EA028801B1/ru not_active IP Right Cessation
- 2014-10-30 UA UAA201603973A patent/UA118767C2/uk unknown
- 2014-10-30 EP EP14802974.7A patent/EP3066108B1/en active Active
- 2014-10-30 MY MYPI2016701635A patent/MY192242A/en unknown
- 2014-10-30 ES ES14802974T patent/ES2703944T3/es active Active
- 2014-10-30 PL PL14802974T patent/PL3066108T3/pl unknown
- 2014-10-30 US US15/026,427 patent/US9573970B2/en active Active
- 2014-10-30 WO PCT/US2014/063161 patent/WO2015069541A1/en active Application Filing
- 2014-10-30 NZ NZ718118A patent/NZ718118A/en unknown
- 2014-10-30 LT LTEP14802974.7T patent/LT3066108T/lt unknown
-
2016
- 2016-03-17 DO DO2016000067A patent/DOP2016000067A/es unknown
- 2016-04-04 IL IL24489916A patent/IL244899B/en active IP Right Grant
- 2016-04-06 CL CL2016000791A patent/CL2016000791A1/es unknown
- 2016-04-06 CR CR20160165A patent/CR20160165A/es unknown
- 2016-05-03 SV SV2016005190A patent/SV2016005190A/es unknown
- 2016-05-06 PH PH12016500851A patent/PH12016500851A1/en unknown
-
2018
- 2018-12-06 HR HRP20182061TT patent/HRP20182061T1/hr unknown
- 2018-12-12 CY CY181101334T patent/CY1121096T1/el unknown
-
2021
- 2021-11-17 AR ARP210103177A patent/AR124083A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1544208A1 (en) * | 2002-08-08 | 2005-06-22 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| WO2013169546A1 (en) * | 2012-05-10 | 2013-11-14 | Eli Lilly And Company | Pyrazole compounds as sglt1 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6148725B2 (ja) | Ｓｇｌｔ１阻害剤としてのピラゾール化合物 | |
| IL223515A (en) | Triazaspiroodecanyl compounds and their uses | |
| BR112020005064A2 (pt) | aminas beta-hidróxi heterocíclicas e seu uso no tratamento de hiperglicemia | |
| TW201639834A (zh) | 新吡啶陽離子化合物 | |
| EA028801B1 (ru) | Новые ингибиторы sglt1 | |
| WO2014055297A1 (en) | Novel urea compounds | |
| KR20130018623A (ko) | Ｎ1-고리아민-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
| AU2014342612B2 (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as SGLT inhibitors | |
| CN106674245B (zh) | 吡喃葡萄糖基衍生物的制备及医药上的应用 | |
| CN115297856A (zh) | 用于治疗糖尿病性视网膜病变的分拣蛋白拮抗剂 | |
| CN114828856A (zh) | 以稠合嘧啶化合物为有效成分的治疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |